In this episode, we interview Dr. Tracy Macaulay about the AFIRE trial and hear her thoughts on the role of aspirin in patients with atrial fibrillation and stable coronary disease.
Episode:
0:00-1:38: Intro
1:39-2:35: Introduction of Dr. Tracy Macaulay
2:36-5:19: AFIRE Trial Overview
5:20-7:14: Initial Thoughts
7:15-10:07: AFIRE Population and Rivaroxaban Dosing
10:08-11:06: Dropping Aspirin
11:07-12:11: What about other anticoagulants?
12:12-13:38: Final Thoughts
13:39-14:50: Closing/Discussion of Funding
References:
- AFIRE Trial: Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019;381:1103-1113.
- OAC-ALONE Trial: Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation: OAC-ALONE Study. Circulation 2019; 139:604–616.
- WARIS-II Trial: Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, Aspirin, or Both after Myocardial Infarction. N Engl J Med 2002;347:969-974.
- J-ROCKET AF Study: Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation — the J-ROCKET AF Study. Circ J 2012;76:2104-11.
- Other: Tanigawa T, Kaneko M, Hashizume K, et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet 2013;28:59-70.
CardioScripts 